"Chris O'Brien Lifehouse is a not-for-profit, comprehensive cancer hospital offering care from screening and prevention to diagnosis, treatment and wellness. As well as specialising in rare and complex cancers, we treat all tumour streams: bowel, colorectal, breast, gastroenterological, leukaemia, lung, mesothelioma, lymphoma, melanoma, skin, myeloma, neurological, pancreatic, urological, bladder, prostate and testicular. We offer the following clinics: skin and melanoma, rapid access prostate, rapid access endoscopy, rapid access hysteroscopy and cancer risk reduction."

During the past decade, Chris O'Brien Lifehouse conducted 132 clinical trials. In the 10-year time frame, 132 clinical trials started and 35 clinical trials were completed, i.e. on average, 26.5% percent of trials that started reached the finish line to date. In the past 5 years, 65 clinical trials started and 25 clinical trials were completed. i.e. 38.5% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Chris O'Brien Lifehouse" #1 sponsor was "Pfizer" with 20 trials, followed by "Hoffmann-La Roche" with 18 trials sponsored, "Amgen" with 11 trials sponsored, "Eli Lilly and Company" with 6 trials sponsored and "Janssen Research & Development, LLC" with 6 trials sponsored. Other sponsors include 87 different institutions and companies that sponsored additional 71 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Chris O'Brien Lifehouse" #1 collaborator was "Merck Sharp & Dohme LLC" with 5 trials as a collaborator, "Australian and New Zealand Urogenital and Prostate Cancer Trials Group" with 4 trials as a collaborator, "Cancer Trials Ireland" with 4 trials as a collaborator, "Astellas Pharma Inc" with 3 trials as a collaborator and "AstraZeneca" with 3 trials as a collaborator. Other collaborators include 78 different institutions and companies that were collaborators in the rest 75 trials.

According to Clinical.Site data, the most researched conditions in "Chris O'Brien Lifehouse" are "Prostate Cancer" (8 trials), "Carcinoma, Non-Small-Cell Lung" (7 trials), "Non-Small Cell Lung Cancer" (7 trials), "Non-small Cell Lung Cancer" (7 trials) and "Advanced Solid Tumor" (5 trials). Many other conditions were trialed in "Chris O'Brien Lifehouse" in a lesser frequency.

Most popular intervention types in "Chris O'Brien Lifehouse" are "Drug" (143 trials), "Biological" (10 trials), "Radiation" (7 trials), "Other" (6 trials) and "Device" (2 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (18 trials), "Carboplatin" (13 trials), "Pembrolizumab" (11 trials), "Cisplatin" (10 trials) and "Docetaxel" (9 trials). Other intervention names were less common.

The vast majority of trials in "Chris O'Brien Lifehouse" are 129 trials for "All" genders, 18 trials for "Male" genders and 6 trials for "Female" genders.

Currently, there are NaN active trials in "Chris O'Brien Lifehouse". undefined are not yet recruiting, 46 are recruiting, 41 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 50 completed trials in Chris O'Brien Lifehouse, undefined suspended trials, and 15 terminated clinical trials to date.

Out of the total trials that were conducted in Chris O'Brien Lifehouse, 51 "Phase 1" clinical trials were conducted, 51 "Phase 2" clinical trials and 61 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 4 trials, and there were also 2 trials that are defined as “Not Applicable".